Results 151 to 160 of about 747,376 (295)

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

An Injectable Metal‐Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post‐Surgical Osteosarcoma Therapy

open access: yesAdvanced Science, EarlyView.
This work designed an injectable metal‐drug supramolecular condensate formed from hafnium ions and alendronate (Hf‐ALN) and loaded with the COX‐2 inhibitor celecoxib (CXB) for synergistic radioimmunotherapy of postoperative osteosarcoma. Mechanistically, upon X‐ray irradiation, Hf enhances radiation energy deposition, ROS generation, and DNA damage ...
Tianhua Xiao   +12 more
wiley   +1 more source

Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

open access: yesMedicina
Background and Objectives: Colorectal cancer (CRC) poses a major global health challenge, with high incidence rates and ongoing treatment debates. Adjuvant chemotherapy benefits for high-risk subgroups, particularly stage II disease, remain controversial.
Goncagul Akdag   +13 more
doaj   +1 more source

Adjuvant chemotherapy for colorectal cancer: age differences in factors influencing patients' treatment decisions

open access: yes, 2013
Mikaela L Jorgensen,1,2 Jane M Young,1,2 Michael J Solomon1,31Surgical Outcomes Research Centre (SOuRCe), Sydney School of Public Health, University of Sydney and Sydney Local Health District, NSW, Australia; 2Cancer Epidemiology and Services Research ...
Jorgensen ML, Young JM, Solomon MJ
core  

Multifunctional Nanovaccine‐Radiotherapy Synergy Drives Anti‐Tumor Immunity via Multi‐Cascade Cell Death for Pancreatic Cancer Therapy

open access: yesAdvanced Science, EarlyView.
Machine‐learning‐driven transcriptomic analysis identifies FSTL3 as a key tumor‐microenvironment regulator in desmoplastic pancreatic adenocarcinoma. A cRGD‐modified liposome co‐loading gemcitabine and siFSTL3 serves as an irradiation‐triggered in situ nanovaccine. It synergizes with radiotherapy to induce ferroptosis and immunogenic cell death through
Chengyi Huang   +11 more
wiley   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

open access: yesAdvanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao   +10 more
wiley   +1 more source

Spatiotemporally Controlled Sequential Chemo‐Immunotherapy Activates Pyroptosis for Robust Anti‐Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
A glutathione and ultrasound dual‐responsive cerasome achieves sequential co‐delivery of gemcitabine and BMS1166 in tumors. Chemotherapy priming followed by on‐demand PD‐L1 blockade synergistically amplifies anti‐tumor immunity, inhibiting primary tumor growth, distant metastasis and inducing durable immune memory.
Suhui Sun   +9 more
wiley   +1 more source

Return‐To‐Work and Working Status After Surgery for Gastric and Esophageal Cancer: A Prospective Observational Study

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
In this multicenter prospective study of 158 working‐age patients undergoing curative‐intent surgery for gastric or esophageal cancer, 78.5% were working at 18 months. Postoperative appetite loss, financial difficulties, and ≥ 10% weight loss at 6 months were associated with non‐working status.
Kentaro Goto   +18 more
wiley   +1 more source

Limited benefit of adjuvant chemotherapy for Asian patients with stage IB lung adenocarcinoma: implications for clinical practice

open access: yesWorld Journal of Surgical Oncology
Backgroud The benefit of adjuvant chemotherapy for patients with stage IB lung adenocarcinoma remains unclear. We compared adjuvant chemotherapy outcomes in Asian and non-Asian stage IB lung adenocarcinoma patients using multi-source clinical data ...
Shaowei Xin   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy